Live tape
Top 8, mentions 7d7,154META1,971 mentions▲ +0.06GOOGL1,488 mentions▲ +0.03NVDA848 mentions▲ +0.09MSFT615 mentions▲ +0.05TSLA601 mentions▲ +0.06SPY563 mentions▲ +0.03MUSE537 mentions▲ +0.06AMZN531 mentions▲ +0.04

Equity · Healthcare

ZLAB

NASDAQ

Zai Lab Limited

$20 −3.66% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
Price · Chart
Our own end-of-day closes 12 sessions
$21 $18 1 Jul 17 Jul

The line runs $19.17 on 1 July through $20 on 17 July, on a scale from $18 to $21. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of ZLAB over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 12 sessions over that window: $19.17 on 1 July 2026 through $20 on 17 July 2026.

Market cap $22.2B
52-week range $16.32 – $40.56
Avg volume 216.8K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Jul 17, 2026

ZLAB insider trades

SEC Form 4 · last 90 days · newest reported trade 19 Aug 2026
Open-market buys 1
Open-market sells 3
Net sold $202K
Non-trade filings 6
Date Insider Type Shares Value
19 Aug 2026 Chen Yajing Chief Financial Officer Sell 260 $7K
12 Aug 2026 Lis William Director Sell 8,506 $213K
11 Aug 2026 Chen Yajing Chief Financial Officer Sell 619 $15K
01 Jul 2026 GAYNOR RICHARD Director Buy 1,736 $33K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
14 Aug 2026 Chen Yajing Chief Financial Officer Option exercise 1,250
14 Aug 2026 Chen Yajing Chief Financial Officer Tax withheld 427 $11K
02 Jul 2026 Du Ying Chairperson & CEO Option exercise 11,048
02 Jul 2026 Du Ying Chairperson & CEO Tax withheld 4,348 $83K
01 Jul 2026 Du Ying Chairperson & CEO Option exercise 18,000
01 Jul 2026 Du Ying Chairperson & CEO Tax withheld 7,083 $136K

ZLAB reported financials

SEC EDGAR XBRL

ZLAB reported revenue of $457.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$175.5M.

Figure Reported Period
Revenue $457.2M 31 Dec 2025 fiscal year
Net income −$175.5M 31 Dec 2025 fiscal year
Diluted EPS −$0.16 31 Dec 2025 fiscal year
Total assets $1.1B 30 Jun 2026 at period end
Total equity $607.0M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

ZLAB earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.05 $106M
31 Mar 2026 Q1 2026 $-0.05 $100M
31 Dec 2025 FY 2025 $-0.16 $460M
30 Sep 2025 Q3 2025 $-0.03 $116M
30 Jun 2025 Q2 2025 $-0.04 $110M
31 Mar 2025 Q1 2025 $-0.04 $106M
31 Dec 2024 FY 2024 $-0.26 $399M
30 Sep 2024 Q3 2024 $-0.04 $102M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ZLAB institutional holders

SEC Form 13F

4 of the 45 institutional funds we track reported a ZLAB position for the quarter ended 30 Jun 2026 — a combined $54.6M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Two Sigma Investments Added +319.5% shares 1,299,394 $24.7M
Citadel Advisors Held (±25%) −23.9% shares 1,284,706 $24.4M
Marshall Wace New position 147,217 $2.8M
D. E. Shaw & Co. Added +123.2% shares 141,158 $2.7M
Point72 Asset Management Exited
Renaissance Technologies Exited

Source: SEC EDGAR 13F filings

ZLAB fails-to-deliver

SEC CNS data

On 31 Aug 2026, 74 shares of ZLAB failed to deliver (about $2K).

Settlement date Shares failed Notional % of shares out
31 Aug 2026 74 $2K <0.001%
27 Aug 2026 39 $1K <0.001%
26 Aug 2026 921 $24K <0.001%
25 Aug 2026 341 $9K <0.001%
24 Aug 2026 22,070 $574K 0.002%
17 Aug 2026 25,154 $651K 0.002%

Source: SEC fails-to-deliver (CNS) data